P-133A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer. (2nd July 2019) - Vermorken, J; Cervantes, A; Morsing, P; Johansson, K; Andersson, T; Roest, N Lindland; Gullbo, J; Salazar, R